Clinical Trial: A Phase II, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golixitinib Addition in Patients with Peripheral T-Cell Lymphoma Demonstrating Suboptimal Response at Interim Assessment of First-Line Therapy (China)

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase II, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golixitinib Addition in Patients with Peripheral T-Cell Lymphoma Demonstrating Suboptimal Response at Interim Assessment of First-Line Therapy'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131819

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Nanjing Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=300283

Published by HT Digital Content Services with permission from Health Daily Digest....